Effects of Indralin on Immunohematological Parameters and DNA Damage in Irradiated ICR (CD-1) Outbred Mice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Abstract—Intragastric administration of radioprotector indralin (B-190 drug) to outbred SPF ICR (CD-1) mice 15 minutes before X-ray irradiation at doses of 6 Gy (LD-10/30), 6.5 Gy, and 7 Gy (LD-100/30) increases the 30-day survival of the animals and positively affects the state of the central organs of immunity and hematopoiesis, as well as the number of peripheral blood leukocytes. In addition, a positive effect on the behavioral reactions of the irradiated animals and striated muscles strength was noted. In addition to these secondary features of the indralin positive effect, a significant reduction of radiation-induced DNA damage in spleenocytes was observed using flow cytometry analysis of phosphorylated histone Н2АХ (γН2АХ) (1 h and eight days after X-ray irradiation) and DNA-comet assay (eight days after X-ray irradiation). The abovementioned methods are recommended for experiments investigating the influence of radioprotective drugs on DNA damage induction and repair in the irradiated organism, as well as for initial searching of potential radioprotectors and assessment of their effectiveness level in clinical practice and experiments.

About the authors

A. Yu. Bushmanov

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

A. N. Osipov

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences

Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow

M. A. Ignatov

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

M. D. Vorontsova

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

T. A. Karaulova

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

A. V. Gordeev

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

E. I. Yashkina

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

O. V. Nikitenko

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences

Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow

T. M. Bychkova

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences

Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow

N. M. Stavrakova

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

I. E. Andrianova

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Email: a1931192@mail.ru
Russian Federation, Moscow

T. M. Blokhina

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences

Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow

N. Yu. Vorobyeva

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences

Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow

A. A. Ivanov

State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences; Joint Institute for Nuclear Research

Author for correspondence.
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow; Dubna


Copyright (c) 2019 Pleiades Publishing, Inc.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies